MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.090
+0.040
+1.95%
After Hours: 2.040 -0.05 -2.39% 17:58 05/11 EDT
OPEN
1.976
PREV CLOSE
2.050
HIGH
2.130
LOW
1.976
VOLUME
440.37K
TURNOVER
--
52 WEEK HIGH
5.42
52 WEEK LOW
1.590
MARKET CAP
44.11M
P/E (TTM)
-1.1338
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 6d ago
DJ Plus Therapeutics Shares Drop 8% After Collaboration Deals
Dow Jones · 05/04 16:59
Thinking about buying stock in Plus Therapeutics, AMC Entertainment, ProQR Therapeutics, Nokia, or Diana Shipping?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, AMC, PRQR, NOK, and DSX.
PR Newswire - PRF · 05/04 13:31
Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract
Plus Therapeutics (PSTV) gains 5% premarket after announcing two collaboration agreements to support its process development and analytical chemistry activities for the cGMP manufacturing of Rhenium NanoLiposome ((RNL)), an investigational asset in clinica...
Seekingalpha · 05/04 12:09
DJ Plus Therapeutics in Two Collaboration Deals for Making Rhenium NanoLiposome
Dow Jones · 05/04 11:59
Plus Therapeutics Announces Key RNL Development And cGMP Drug Manufacturing Collaboration Agreements
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced two
Benzinga · 05/04 11:40
22 Stocks Moving in Monday's Pre-Market Session
Gainers
Benzinga · 05/03 11:02
DJ Plus Therapeutics, Inc. CEO Marc Hedrick on Q1 2021 Results -- Earnings Call Transcript >PSTV
Dow Jones · 04/23 11:58
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTV. Analyze the recent business situations of Plus Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTV stock price target is 6.81 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 384.29K
% Owned: 1.82%
Shares Outstanding: 21.11M
TypeInstitutionsShares
Increased
5
119.66K
New
2
38.76K
Decreased
5
14.87K
Sold Out
4
104.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
Richard Hawkins
President
Steven Kesten
Chief Executive Officer/Director
Marc Hedrick
Chief Financial Officer/Vice President - Finance
Andrew Sims
Corporate Executive
Seijiro Shirahama
Senior Vice President
Gregory Stein
Chief Accounting Officer/Controller
Desiree Smith
Vice President - Business Development/General Counsel
Jeremy Hayden
Other
Mark Marino
Independent Director
Howard Clowes
Independent Director
Robert Lenk
Independent Director
Greg Petersen
Independent Director
Annigje van Es-Johansson
No Data
About PSTV
Plus Therapeutics, Inc., formerly Cytori Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.

Webull offers kinds of Plus Therapeutics Inc stock information, including NASDAQ:PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.